22nd Aug 2014 07:00
22 August 2014
Biofrontera AG
("Biofrontera" or the "Company")
Notice of Half Year Results
Biofrontera AG (AIM:B8F), the European biopharmaceutical company, will be announcing its half year results for the six months period ending 30 June 2014 on 29 August 2014.
There is a conference call for shareholders and interested investors on August 29, 2014 at the following times:
9.00am CET (8.00am UK) conference call in German: Dial-in number: +49-(0)69 271340800
Room number: 87293438#
10.30am CET (9.30am UK) conference call in English Dial-in number: +44 20336 45807
Room number: 87293438#
Enquiries:
Biofrontera AG Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer, Chief Financial Officer Anke zur Mühlen, Corporate Communications
| +49 (0) 214 87 63 2 0 www.biofrontera.com
|
finnCap (Nomad and Broker) Geoff Nash / Christopher Raggett (Corporate FinanceSteven Norcross(Corporate Broking)
| +44(0) 20 7220 0500 |
Seton Services Limited (IR) Toni Vallen
| +44 (0) 20 7603 6797 |
Gable Communications John Bick | +44 (0) 20 7193 7463 +44 (0) 7872 061007 |
Notes to Editors:
Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz® for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.
In addition, the Company markets the Belixos® cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.
www.biofrontera.com
Related Shares:
B8F.L